文献速递妇科生殖医学

纵隔子宫女性行子宫纵隔切除术:一项队列研究

Septum resection in women with a septate uterus: a cohort study.
PubMed 文献 · Hum Reprod · 2020-01-01

该国际多中心回顾性队列研究纳入257例子宫纵隔女性,比较纵隔切除术与期待管理的生殖结局。结果显示,切除术未提高活产率(53.0% vs 71.7%,HR 0.71,95%CI 0.49-1.02),也未降低流产、早产或胎位异常率。

要点

  • 纵隔切除术未增加活产率,HR 0.71(95%CI 0.49-1.02)。
  • 切除术组流产率46.8%,期待组34.4%,OR 1.58(0.81-3.09)。
  • 早产和胎位异常率两组无显著差异。

核心结论

  • 对于纵隔子宫女性,与期待管理相比,纵隔切除术不增加活产率,也不降低流产率或早产率。

研究设计与样本

  • 国际多中心回顾性队列研究,纳入2000年1月至2018年8月荷兰、美国、英国21个中心的257例子宫纵隔女性。

主要发现

  • 纵隔切除术组151例,期待管理组106例,中位随访46个月。
  • 活产:切除术组80例(53.0%),期待组76例(71.7%),HR 0.71(95%CI 0.49-1.02)。
  • 持续妊娠:切除术组89例(58.9%),期待组80例(75.5%),HR 0.74(95%CI 0.52-1.06)。
  • 流产:切除术组51例(46.8%),期待组31例(34.4%),OR 1.58(95%CI 0.81-3.09)。
  • 早产:切除术组26例(29.2%),期待组13例(16.7%),OR 1.26(95%CI 0.52-3.04);胎位异常:切除术组17例(19.1%),期待组27例(34.6%),OR 0.56(95%CI 0.24-1.33)。

关键数值与推荐

  • 纵隔子宫患病率估计为育龄女性的0.2-2.3%,取决于分类系统。
  • 当前指南基于低质量证据推荐切除子宫内纵隔,或更谨慎地建议该手术应在未来研究中评估。

临床怎么用

  • 纵隔切除术广泛开展且有经济成本,但本研究提示其未改善生殖结局,决策时应与患者充分沟通。
  • 研究结果需随机临床试验确认。

局限性

  • 回顾性设计不如随机对照试验稳健。
  • 纵隔子宫定义随时间变化,但纳入者均由当时主治医师按当时主流分类系统诊断。
  • 尽管校正了最相关患者特征,估计值仍可能存在残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does septum resection improve reproductive outcomes in women with a septate uterus? SUMMARY ANSWER: In women with a septate uterus, septum resection does not increase live birth rate nor does it decrease the rates of pregnancy loss or preterm birth, compared with expectant management. WHAT IS KNOWN ALREADY: The septate uterus is the most common uterine anomaly with an estimated prevalence of 0.2-2.3% in women of reproductive age, depending on the classification system. The definition of the septate uterus has been a long-lasting and ongoing subject of debate, and currently two classification systems are used worldwide. Women with a septate uterus may be at increased risk of subfertility, pregnancy loss, preterm birth and foetal malpresentation. Based on low quality evidence, current guidelines recommend removal of the intrauterine septum or, more cautiously, state that the procedure should be evaluated in future studies. STUDY DESIGN, SIZE, DURATION: We performed an international multicentre cohort study in which we identified women mainly retrospectively by searching in electronic patient files, medical records and databases within the time frame of January 2000 until August 2018. Searching of the databases, files and records took place between January 2016 and July 2018. By doing so, we collected data on 257 women with a septate uterus in 21 centres in the Netherlands, USA and UK. PARTICIPANTS/MATERIALS, SETTING, METHODS: We included women with a septate uterus, defined by the treating physician, according to the classification system at that time. The women were ascertained among those with a history of subfertility, pregnancy loss, preterm birth or foetal malpresentation or during a routine diagnostic procedure. Allocation to septum resection or expectant management was dependent on the reproductive history and severity of the disease. We excluded women who did not have a wish to conceive at time of diagnosis. The primary outcome was live birth. Secondary outcomes included pregnancy loss, preterm birth and foetal malpresentation. All conceptions during follow-up were registered but for the comparative analyses, only the first live birth or ongoing pregnancy was included. To evaluate differences in live birth and ongoing pregnancy, we used Cox proportional regression to calculate hazard rates (HRs) and 95% CI. To evaluate differences in pregnancy loss, preterm birth and foetal malpresentation, we used logistic regression to calculate odds ratios (OR) with corresponding 95% CI. We adjusted all reproductive outcomes for possible confounders. MAIN RESULTS AND THE ROLE OF CHANCE: In total, 257 women were included in the cohort. Of these, 151 women underwent a septum resection and 106 women had expectant management. The median follow-up time was 46 months. During this time, live birth occurred in 80 women following a septum resection (53.0%) compared to 76 women following expectant management (71.7%) (HR 0.71 95% CI 0.49-1.02) and ongoing pregnancy occurred in 89 women who underwent septum resection (58.9%), compared to 80 women who had expectant management (75.5%) (HR 0.74 (95% CI 0.52-1.06)). Pregnancy loss occurred in 51 women who underwent septum resection (46.8%) versus 31 women who had expectant management (34.4%) (OR 1.58 (0.81-3.09)), while preterm birth occurred in 26 women who underwent septum resection (29.2%) versus 13 women who had expectant management (16.7%) (OR 1.26 (95% CI 0.52-3.04)) and foetal malpresentation occurred in 17 women who underwent septum resection (19.1%) versus 27 women who had expectant management (34.6%) (OR 0.56 (95% CI 0.24-1.33)). LIMITATIONS, REASONS FOR CAUTION: Our retrospective study has a less robust design compared with a randomized controlled trial. Over the years, the ideas about the definition of the septate uterus has changed, but since the 257 women with a septate uterus included in this study had been diagnosed by their treating physician according to the leading classification system at that time, the data of this study reflect the daily practice of recent decades. Despite correcting for the most relevant patient characteristics, our estimates might not be free of residual confounding. WIDER IMPLICATIONS OF THE FINDINGS: Our results suggest that septum resection, a procedure that is widely offered and associated with financial costs for society, healthcare systems or individuals, does not lead to improved reproductive outcomes compared to expectant management for women with a septate uterus. The results of this study need to be confirmed in randomized clinical trials. STUDY FUNDING/COMPETING INTEREST(S): A travel for JFWR to Chicago was supported by the Jo Kolk Studyfund. Otherwise, no specific funding was received for this study. The Department of Obstetrics and Gynaecology, University Medical Centre, Groningen, received an unrestricted educational grant from Ferring Pharmaceutical Company unrelated to the present study. BWM reports grants from NHMRC, personal fees from ObsEva, personal fees from Merck, personal fees from Guerbet, other payment from Guerbet and grants from Merck, outside the submitted work. The other authors declare no conficts of interest. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Rikken JFW, Verhorstert KWJ, Emanuel MH, et al. Septum resection in women with a septate uterus: a cohort study. Hum Reprod. 2020. PMID: 32353142. doi:10.1093/humrep/dez284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。